Study #2022-1049
A phase 1b study to evaluate the safety, tolerability and preliminary efficacy of ATP150/ATP152, VSV-GP154 and Ezabenlimab (BI 754091) in patients with KRAS G12D/G12V mutated pancreatic ductal adenocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
VSV-GP154, ATP150, ATP152, Ezabenlimab
Description
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Pancreatic Ductal Adenocarcinoma
Study phase:
Phase I
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-751-0416
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.